Yu Zhang, MD, PhD
Assistant Professor of Medicine (Medical Oncology)Cards
About
Research
Publications
2026
DZ-1-artesunate conjugate induces mitochondria-mediated, reactive oxygen species-dependent apoptosis in colorectal cancer tumoroids
Narayanasamy B, Zhang Y, Gangi A, Figlin R, Sargsyan K, Lee H, Song C, Lee Y. DZ-1-artesunate conjugate induces mitochondria-mediated, reactive oxygen species-dependent apoptosis in colorectal cancer tumoroids. Frontiers In Pharmacology 2026, 17: 1743141. DOI: 10.3389/fphar.2026.1743141.Peer-Reviewed Original ResearchMitochondrial localizationDisruption of mitochondrial membrane potentialMitochondria-mediated reactive oxygen speciesReactive oxygen speciesReactive oxygen species-dependent apoptosisMitochondria-targeted anticancer agentsMitochondrial membrane potentialJC-1 assayMitochondria-mediatedPropidium iodide stainingCell polarityJC-1Anticancer activityMitoTracker stainingCell culture modelThree-dimensional architectureIodide stainingMechanical signalsApoptosisMembrane potentialOxygen speciesFresh tissue samplesImmunoblot assayTumoricidal efficacyPlastic surfacesA small molecule inhibitor of ARF GTPase protein 1 limits liver and colon cancer cell growth and metastasis
Peng H, Chhimwal J, Fan W, Wang J, Barbier-Torres L, Sinha S, Chatterjee A, Zhang Y, Tomasi M, Mato J, Murali R, Lu S. A small molecule inhibitor of ARF GTPase protein 1 limits liver and colon cancer cell growth and metastasis. Cell Death & Disease 2026, 17: 238. PMID: 41720764, PMCID: PMC12948951, DOI: 10.1038/s41419-026-08477-8.Peer-Reviewed Original ResearchConceptsSmall molecule inhibitorsColon cancer cell growthAnkyrin repeat domainAnaphase Promoting ComplexG2/M cell cycle arrestRAS-RAF-MEK-ERK signalingMethionine adenosyltransferase 2BCell cycle arrestProtein 1Colon cancer cellsCancer cell growthSmall moleculesAnti-cancer effectsCRC growthRepeat domainPromoter complexCyclin B1 expressionGIT1Scaffold proteinLowering interactionsMitosis arrestCycle arrestMEK activityCyclin B1Cyclin D1 expressionThe Physiology Of the WEight Reduced State (POWERS) study: strategies for the analysis of biological specimens
Gallagher D, Leibel R, Mayer L, Rosenbaum M, Ashby-Thompson M, Benasi G, Foerde K, Goldsmith R, Hirano M, LeDuc C, Roberto C, Seid H, St-Onge M, Whyte K, Zhang Y, Aparicio A, Dratsky D, Gu J, Horowitz M, Lin S, McMath A, Mikula C, Nunez J, Picard M, Schebendach J, Sun Y, Wong A, Yu W, Goodpaster B, Roberts S, Lowe M, Gomez A, Meierovich S, Saks R, Scharf M, Williams E, Zhou A, Zhu O, Allison K, Hayes M, Rickels M, Roalf D, Wu G, Zamani P, Chau L, Czernuszenko A, Demastus C, Fernando M, Ghias K, Grosso G, Herman L, Holmes N, Mastracchio C, Sayana V, Wellman N, Das S, Fielding R, Howland A, Burger K, Speakman J, Hambly C, Belle S, King W, Hallam D, Haller T, Kelley S, Kline C, Leonard K, Pelesko A, Zourelias M, Benos P, Jakicic J, Wahed A, Erickson K, Laughlin M, Yanovski S, Kowtha B, Young-Hyman D. The Physiology Of the WEight Reduced State (POWERS) study: strategies for the analysis of biological specimens. International Journal Of Obesity 2026, 1-7. PMID: 41644794, DOI: 10.1038/s41366-025-01944-w.Peer-Reviewed Original ResearchWeight-reduced statePeripheral blood mononuclear cellsBody mass indexWeight lossSupervised weight lossRegulation of energy balanceBlood mononuclear cellsIntentional weight lossPrimary outcome variableMulti-center clinical trialWeight regainMeal challengeMononuclear cellsMass indexClinical trialsLifestyle interventionSkeletal muscle tissueCellular basisOutcome measuresHealthy adultsHomeostatic mechanismsUS adultsWeight changeVariables of weightOutcome variablesSurvival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial
Foran J, Sun Z, Luger S, Claxton D, Lazarus H, Arber D, Rowe J, Paietta E, Racevskis J, Garrett-Bakelman F, Zhang Y, Altman J, Al-Kali A, Zheng H, Pratz K, Broun E, Powell B, O’Dwyer K, Godwin J, Ofran Y, Litzow M, Tallman M. Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial. Blood Neoplasia 2026, 3: 100194. PMID: 41890705, PMCID: PMC13014643, DOI: 10.1016/j.bneo.2026.100194.Peer-Reviewed Original ResearchAcute myeloid leukemiaMRD-negative remissionInduction mortalityOverall survivalIntensive therapyMyeloid leukemiaAssociated with 5-year OSSecond-generation purine nucleoside analogNewly diagnosed AMLProspective phase 3 studySecondary acute myeloid leukemiaStandard-intensity therapyMedian Follow-UpAssociated with OSPhase 3 studyMultiparameter flow cytometryPhase 3 trialLow-intensity therapyLong-term outcomesPurine nucleoside analogsNon-inferiority designMRD-positiveInferior OSMRD negativityComplete remissionThe Physiology Of the WEight Reduced State (POWERS) study: design and rationale for assessment of food intake, physical activity and other behavioral constructs
Leibel R, Mayer L, Rosenbaum M, Goldsmith R, Hirano M, LeDuc C, Roberto C, Seid H, St-Onge M, Whyte K, Zhang Y, Aparicio A, Dratsky D, Goodpaster B, Gu J, Horowitz M, Lin S, McMath A, Mikula C, Nunez J, Picard M, Schebendach J, Sun Y, Wong A, Yu W, Burger K, Das S, Fielding R, Rickels M, Roalf D, Speakman J, Wu G, Zamani P, Chau L, Czernuszenko A, Demastus C, Fernando M, Ghias K, Gomez A, Grosso G, Hambly C, Herman L, Holmes N, Howland A, Mastracchio C, Meierovich S, Saks R, Sayana V, Scharf M, Wellman N, Williams E, Zhou A, Zhu O, Belle S, Benos P, Wahed A, Erickson K, Hallam D, Haller T, Kelley S, Leonard K, Pelesko A, Zourelias M, Kowtha B, Yanovski S. The Physiology Of the WEight Reduced State (POWERS) study: design and rationale for assessment of food intake, physical activity and other behavioral constructs. International Journal Of Obesity 2026, 1-8. PMID: 41514047, DOI: 10.1038/s41366-025-01991-3.Peer-Reviewed Original ResearchSelf-report questionnairesWeight loss maintenanceWeight-reduced statePhysical activityFree-living physical activityBehavioral weight loss programEating-related behaviorsLong-term sustained weight lossNIH-funded clinical trialsComputer-based tasksWeight lossEnergy intakeAssessment of food intakeComponents of energy expenditureEnergy expenditureSustained weight lossNeurocognitive factorsStructural neuroimagingWeight loss programBehavioral measuresBody mass indexNeural circuitryBehavioral assessmentLaboratory mealBehavioral constructs
2025
The Physiology Of the WEight Reduced State (POWERS) study: overview and study design
Mayer L, Ashby-Thompson M, Benasi G, Foerde K, Goldsmith R, Hirano M, LeDuc C, Roberto C, Seid H, St-Onge M, Whyte K, Zhang Y, Aparicio A, Dratsky D, Goodpaster B, Gu J, Horowitz M, Lin S, McMath A, Mikula C, Nunez J, Picard M, Schebendach J, Sun Y, Wong A, Yu W, Burger K, Fielding R, Rickels M, Roalf D, Speakman J, Wu G, Zamani P, Chau L, Czernuszenko A, Demastus C, Fernando M, Ghias K, Gomez A, Grosso G, Hambly C, Herman L, Holmes N, Howland A, Mastracchio C, Meierovich S, Sayana V, Scharf M, Wellman N, Williams E, Zhou A, Zhu O, Benos P, Wahed A, Erickson K, Hallam D, Haller T, Kelley S, Kline C, Leonard K, Pelesko A, Zourelias M, Kowtha B, Laughlin M, Yanovski S, Young-Hyman D. The Physiology Of the WEight Reduced State (POWERS) study: overview and study design. International Journal Of Obesity 2025, 1-9. PMID: 41388149, DOI: 10.1038/s41366-025-01932-0.Peer-Reviewed Original ResearchWeight-reduced stateEnergy intakeIntentional weight lossPrimary independent variableEnergy expenditureLower body mass indexWeight lossSelf-report questionnairesBody mass indexWeight changeWL interventionBehavioral interventionsStudy designMass indexWL programPrimary outcomeLife expectancyObjective measuresMetabolic adaptationClinical benefitLost weightClinical centersWeight variabilityMultifactorial diseaseInterventionDual roles of complement in ulcerative colitis: insights from clinical studies and animal research
Qin Z, Wang R, Zhang Y. Dual roles of complement in ulcerative colitis: insights from clinical studies and animal research. European Journal Of Medical Research 2025, 30: 1234. PMID: 41388435, PMCID: PMC12699900, DOI: 10.1186/s40001-025-03400-x.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseUlcerative colitisMannose-binding lectinMucosal inflammationMembrane attack complexComplement activationComplement-targeted therapyEpithelial barrier disruptionChronic mucosal inflammationComplement systemDextran sulfate sodium (DSS)-induced murine colitis modelMurine colitis modelEpithelial injuryPrecision treatment strategiesApoptotic cell clearanceNeutrophil recruitmentComplement inhibitorsTreatment strategiesClinical studiesBarrier disruptionUC pathogenesisImmune regulationCytokine stormColitis modelBowel diseaseA Bioorthogonal TCO–Tetrazine-Based Pretargeted PET/NIRF Platform Enabling High-Contrast Tumor Imaging
Huang M, Wang W, Yu Q, Zhou Y, Wang Y, Wang R, Li X, Zhou Y, Zhang Y, Tian R. A Bioorthogonal TCO–Tetrazine-Based Pretargeted PET/NIRF Platform Enabling High-Contrast Tumor Imaging. Pharmaceuticals 2025, 18: 1874. PMID: 41471363, PMCID: PMC12735951, DOI: 10.3390/ph18121874.Peer-Reviewed Original ResearchHigh-contrast tumor imagesConclusions:Methods:Pretargeting systemTumor-to-muscle ratioResults:PET imagingPeak tumor uptakeTumor-bearing miceU87MG tumor-bearing miceTumor imagingNear-infrared fluorescence imagingOff-target accumulationTumor-targeting characteristicsSmall-molecule agentsSystemic exposureTumor uptakeTumor accumulationPretargeting intervalPretargeting strategyRadiopharmaceutical imagingRadionuclide deliveryTumorRadiochemical stabilityOptimal uptakeA novel IKZF1::FAM3C fusion associated with inversion of chromosome 7, inv(7)(p13q32), in relapsed acute myeloid leukemia
Tang H, Yan M, Zhang Y, Yao J. A novel IKZF1::FAM3C fusion associated with inversion of chromosome 7, inv(7)(p13q32), in relapsed acute myeloid leukemia. Journal Of Hematopathology 2025, 18: 55. PMID: 41269428, DOI: 10.1007/s12308-025-00669-z.Peer-Reviewed Original ResearchConceptsChromosome 7Inversion of chromosome 7B-cell acute lymphoblastic leukemiaShort armPericentric inversionShort arm of chromosome 7Myeloid leukemiaPericentric inversion of chromosome 7Allogeneic stem cell transplantationRelapsed acute myeloid leukemiaBackgroundAcute myeloid leukemiaStem cell transplantationAcute myeloid leukemiaRNA sequencingAcute lymphoblastic leukemiaIkaros functionGene fusionsIKZF1 geneKaryotype analysisAML pathogenesisCase presentationHereIKZF1 deletionsRelapsed AMLMyeloid blastsDisease relapseThe Physiology Of the WEight Reduced State (POWERS) study: assessing energy balance
Gallagher D, Leibel R, Mayer L, Rosenbaum M, Ashby-Thompson M, Benasi G, Foerde K, Goldsmith R, Hirano M, LeDuc C, Roberto C, Seid H, St-Onge M, Whyte K, Zhang Y, Aparicio A, Dratsky D, Gu J, Horowitz M, Lin S, McMath A, Mikula C, Nunez J, Picard M, Schebendach J, Sun Y, Wong A, Yu W, Goodpaster B, Roberts S, Lowe M, Gomez A, Meierovich S, Saks R, Scharf M, Williams E, Zhou A, Zhu O, Allison K, Hayes M, Rickels M, Roalf D, Wu G, Zamani P, Chau L, Czernuszenko A, Demastus C, Fernando M, Ghias K, Grosso G, Herman L, Holmes N, Mastracchio C, Sayana V, Wellman N, Krupa Das S, Fielding R, Howland A, Burger K, Speakman J, Hambly C, Belle S, King W, Hallam D, Haller T, Kelley S, Kline C, Leonard K, Pelesko A, Zourelias M, Benos P, Jakicic J, Wahed A, Erickson K, Laughlin M, Yanovski S, Kowtha B, Young-Hyman D. The Physiology Of the WEight Reduced State (POWERS) study: assessing energy balance. International Journal Of Obesity 2025, 1-9. PMID: 41249847, DOI: 10.1038/s41366-025-01935-x.Peer-Reviewed Original ResearchTwenty-four-hour energy expenditureDual X-ray absorptiometryResting Energy ExpenditureBody mass indexWeight-reduced stateBehavioral weight lossEnergy intakeWeight lossWeight regainSelf-reported dietary intakeEnergy expenditureSupervised weight lossX-ray absorptiometryPost-weight lossPrimary outcome variableActivity energy expenditureDietary intakeLean massMass indexGrip strengthWeight stabilityPrimary dependent variableHealthy adultsDiscussionThis manuscriptBody weight